Safety in Lactation: Drugs for hypertension

23 September 2020Additional information relating to breastfeeding To be used in conjunction with individual drug entries for specific information and guidance. Many of the drugs covered by…

How should ankle oedema caused by calcium channel blockers be treated?

1 June 2020Ankle oedema is a common, often troublesome adverse effect for patients who are receiving calcium channel blocker (CCB) therapy, and may affect compliance. It is…

What are the reported incidences of ankle oedema with different calcium channel blockers?

1 June 2020The potential to cause ankle oedema appears to exist for all calcium channel blocking agents, and is caused by increasing capillary pressure leading to leakage…
Search Articles

Medicine Compliance Aid Stability

MotensGlaxoSmithKline UK

GlaxoSmithKline UK
Tablets 2mg, 4mg
A3 · Amber 3No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Protect from light
Light sensitive tablets so protection from light is essential.
9 November 2015

Lactation Safety Information

Nifedipine, Verapamil
No published evidence of safety
Monitor infant for adverse effects
16 January 2017